Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.67
GILD's Cash to Debt is ranked higher than
53% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. GILD: 0.67 )
GILD' s 10-Year Cash to Debt Range
Min: 0.15   Max: No Debt
Current: 0.67

Equity to Asset 0.47
GILD's Equity to Asset is ranked higher than
61% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GILD: 0.47 )
GILD' s 10-Year Equity to Asset Range
Min: 0.21   Max: 0.95
Current: 0.47

0.21
0.95
Interest Coverage 14.74
GILD's Interest Coverage is ranked higher than
51% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GILD: 14.74 )
GILD' s 10-Year Interest Coverage Range
Min: 5.85   Max: 2509.2
Current: 14.74

5.85
2509.2
F-Score: 8
Z-Score: 9.17
M-Score: -2.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 58.62
GILD's Operating margin (%) is ranked higher than
99% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. GILD: 58.62 )
GILD' s 10-Year Operating margin (%) Range
Min: -718.37   Max: 54.68
Current: 58.62

-718.37
54.68
Net-margin (%) 45.45
GILD's Net-margin (%) is ranked higher than
97% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. GILD: 45.45 )
GILD' s 10-Year Net-margin (%) Range
Min: -638.78   Max: 40.13
Current: 45.45

-638.78
40.13
ROE (%) 72.02
GILD's ROE (%) is ranked higher than
99% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. GILD: 72.02 )
GILD' s 10-Year ROE (%) Range
Min: -49.14   Max: 61.24
Current: 72.02

-49.14
61.24
ROA (%) 35.33
GILD's ROA (%) is ranked higher than
98% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. GILD: 35.33 )
GILD' s 10-Year ROA (%) Range
Min: -30.31   Max: 32.56
Current: 35.33

-30.31
32.56
ROC (Joel Greenblatt) (%) 388.41
GILD's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. GILD: 388.41 )
GILD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -127.04   Max: 187.3
Current: 388.41

-127.04
187.3
Revenue Growth (%) 13.30
GILD's Revenue Growth (%) is ranked higher than
87% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. GILD: 13.30 )
GILD' s 10-Year Revenue Growth (%) Range
Min: 5.3   Max: 128.9
Current: 13.3

5.3
128.9
EBITDA Growth (%) 5.40
GILD's EBITDA Growth (%) is ranked higher than
83% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. GILD: 5.40 )
GILD' s 10-Year EBITDA Growth (%) Range
Min: -26.3   Max: 119
Current: 5.4

-26.3
119
EPS Growth (%) 2.90
GILD's EPS Growth (%) is ranked higher than
82% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. GILD: 2.90 )
GILD' s 10-Year EPS Growth (%) Range
Min: -20.6   Max: 153.3
Current: 2.9

-20.6
153.3
» GILD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

GILD Guru Trades in Q4 2013

Louis Moore Bacon 300,000 sh (New)
Ray Dalio 38,621 sh (New)
Paul Tudor Jones 7,997 sh (New)
John Rogers 324,302 sh (+396.9%)
Daniel Loeb 1,500,000 sh (+200%)
Pioneer Investments 2,884,918 sh (+70.12%)
Steven Cohen 63,000 sh (+27.71%)
Julian Robertson 320,001 sh (+25.84%)
Jeremy Grantham 3,386,737 sh (+15.89%)
Mario Gabelli 33,605 sh (+7.35%)
Ken Fisher 1,010,705 sh (+3.41%)
Ronald Muhlenkamp 192,795 sh (+2.89%)
Jean-Marie Eveillard 400 sh (unchged)
Stanley Druckenmiller 610,700 sh (unchged)
Caxton Associates Sold Out
George Soros Sold Out
John Hussman Sold Out
Mariko Gordon 15,452 sh (-3.02%)
RS Investment Management 162,480 sh (-14.7%)
David Rolfe 1,800,984 sh (-28.36%)
Vanguard Health Care Fund 4,630,700 sh (-28.62%)
John Griffin 620,000 sh (-68.21%)
» More
Q1 2014

GILD Guru Trades in Q1 2014

Jim Simons 189,353 sh (New)
John Burbank 3,619 sh (New)
George Soros 50,000 sh (New)
Caxton Associates 50,000 sh (New)
Louis Moore Bacon 2,239,590 sh (+646.53%)
Ray Dalio 247,721 sh (+541.42%)
Steven Cohen 207,778 sh (+229.81%)
Paul Tudor Jones 10,805 sh (+35.11%)
Mario Gabelli 44,240 sh (+31.65%)
John Rogers 397,273 sh (+22.5%)
Mariko Gordon 18,089 sh (+17.07%)
Pioneer Investments 3,349,807 sh (+16.11%)
RS Investment Management 180,214 sh (+10.91%)
Julian Robertson 345,320 sh (+7.91%)
David Rolfe 1,907,287 sh (+5.9%)
Jean-Marie Eveillard 400 sh (unchged)
Caxton Associates 60,000 sh (unchged)
Paul Tudor Jones 75,000 sh (unchged)
Daniel Loeb Sold Out
John Griffin Sold Out
Stanley Druckenmiller Sold Out
Ronald Muhlenkamp 192,015 sh (-0.4%)
Ken Fisher 601,758 sh (-40.46%)
Vanguard Health Care Fund 2,713,300 sh (-41.41%)
Jeremy Grantham 516,946 sh (-84.74%)
» More
Q2 2014

GILD Guru Trades in Q2 2014

Alan Fournier 2,070,000 sh (New)
Joel Greenblatt 466,853 sh (New)
Ken Heebner 1,710,000 sh (New)
Ken Fisher 975,483 sh (+62.11%)
John Rogers 638,734 sh (+60.78%)
Ray Dalio 349,821 sh (+41.22%)
Julian Robertson 443,911 sh (+28.55%)
Pioneer Investments 3,899,022 sh (+16.4%)
Mario Gabelli 49,170 sh (+11.14%)
RS Investment Management 192,614 sh (+6.88%)
John Burbank 3,774 sh (+4.28%)
Jean-Marie Eveillard 400 sh (unchged)
Caxton Associates 100,000 sh (unchged)
Louis Moore Bacon Sold Out
David Rolfe Sold Out
George Soros Sold Out
Caxton Associates Sold Out
Jim Simons 166,648 sh (-11.99%)
Paul Tudor Jones 9,304 sh (-13.89%)
Ronald Muhlenkamp 144,715 sh (-24.63%)
Mariko Gordon 11,654 sh (-35.57%)
Vanguard Health Care Fund 1,633,700 sh (-39.79%)
Jeremy Grantham 10,600 sh (-97.95%)
» More
Q3 2014

GILD Guru Trades in Q3 2014

Dodge & Cox 4,800 sh (New)
David Dreman 2,388 sh (New)
Louis Moore Bacon 11,734 sh (New)
Stanley Druckenmiller 217,500 sh (New)
Paul Tudor Jones 30,245 sh (+225.08%)
John Burbank 12,073 sh (+219.9%)
Ronald Muhlenkamp 206,350 sh (+42.59%)
Joel Greenblatt 664,223 sh (+42.28%)
John Rogers 643,896 sh (+0.81%)
Jean-Marie Eveillard 400 sh (unchged)
Julian Robertson 443,911 sh (unchged)
Jim Simons Sold Out
Ken Heebner 1,560,000 sh (-8.77%)
Pioneer Investments 3,536,065 sh (-9.31%)
Alan Fournier 1,861,000 sh (-10.1%)
Mariko Gordon 10,366 sh (-11.05%)
Mario Gabelli 42,600 sh (-13.36%)
RS Investment Management 151,879 sh (-21.15%)
Ken Fisher 763,423 sh (-21.74%)
Ray Dalio 241,521 sh (-30.96%)
Jeremy Grantham 6,700 sh (-36.79%)
Vanguard Health Care Fund 379,200 sh (-76.79%)
» More
» Details

Insider Trades

Latest Guru Trades with GILD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ronald Muhlenkamp 2014-09-30 Add 42.59%1.19%$85.07 - $109.43 $ 105.548%206350
Ken Heebner 2014-09-30 Reduce -8.77%0.33%$85.07 - $109.43 $ 105.548%1560000
Vanguard Health Care Fund 2014-09-30 Reduce -76.79%0.28%$85.07 - $109.43 $ 105.548%379200
Joel Greenblatt 2014-09-30 Add 42.28%0.21%$85.07 - $109.43 $ 105.548%664223
Ray Dalio 2014-09-30 Reduce -30.96%0.07%$85.07 - $109.43 $ 105.548%241521
Ken Fisher 2014-09-30 Reduce -21.74%0.04%$85.07 - $109.43 $ 105.548%763423
David Dreman 2014-09-30 New Buy0.02%$85.07 - $109.43 $ 105.548%2388
John Burbank 2014-09-30 Add 219.9%0.01%$85.07 - $109.43 $ 105.548%12073
Dodge & Cox 2014-09-30 New Buy$85.07 - $109.43 $ 105.548%4800
Ken Heebner 2014-06-30 New Buy3.8%$65.48 - $83.02 $ 105.5436%1710000
Julian Robertson 2014-06-30 Add 28.55%2.98%$65.48 - $83.02 $ 105.5436%443911
Ronald Muhlenkamp 2014-06-30 Reduce -24.63%0.59%$65.48 - $83.02 $ 105.5436%144715
Joel Greenblatt 2014-06-30 New Buy0.48%$65.48 - $83.02 $ 105.5436%466853
John Rogers 2014-06-30 Add 60.78%0.25%$65.48 - $83.02 $ 105.5436%638734
Vanguard Health Care Fund 2014-06-30 Reduce -39.79%0.21%$65.48 - $83.02 $ 105.5436%1633700
Ken Fisher 2014-06-30 Add 62.11%0.07%$65.48 - $83.02 $ 105.5436%975483
Ray Dalio 2014-06-30 Add 41.22%0.06%$65.48 - $83.02 $ 105.5436%349821
George Soros 2014-06-30 Sold Out 0.04%$65.48 - $83.02 $ 105.5436%0
Mariko Gordon 2014-06-30 Reduce -35.57%0.02%$65.48 - $83.02 $ 105.5436%11654
Daniel Loeb 2014-03-31 Sold Out 1.9%$68.55 - $83.95 $ 105.5434%0
Julian Robertson 2014-03-31 Add 7.91%0.59%$68.55 - $83.95 $ 105.5434%345320
John Griffin 2014-03-31 Sold Out 0.48%$68.55 - $83.95 $ 105.5434%0
Vanguard Health Care Fund 2014-03-31 Reduce -41.41%0.46%$68.55 - $83.95 $ 105.5435%2713300
Ray Dalio 2014-03-31 Add 541.42%0.12%$68.55 - $83.95 $ 105.5434%247721
Ken Fisher 2014-03-31 Reduce -40.46%0.07%$68.55 - $83.95 $ 105.5435%601758
John Rogers 2014-03-31 Add 22.5%0.06%$68.55 - $83.95 $ 105.5434%397273
George Soros 2014-03-31 New Buy0.04%$68.55 - $83.95 $ 105.5434%50000
John Burbank 2014-03-31 New Buy0.01%$68.55 - $83.95 $ 105.5434%3619
Mario Gabelli 2014-03-31 Add 31.65%$68.55 - $83.95 $ 105.5434%44240
Julian Robertson 2013-12-31 Add 25.84%1.52%$58.9 - $75.2 $ 105.5452%320001
Daniel Loeb 2013-12-31 Add 200%1.27%$58.9 - $75.2 $ 105.5452%1500000
John Griffin 2013-12-31 Reduce -68.21%1.02%$58.9 - $75.2 $ 105.5452%620000
John Hussman 2013-12-31 Sold Out 0.86%$58.9 - $75.2 $ 105.5452%0
Vanguard Health Care Fund 2013-12-31 Reduce -28.62%0.4%$58.9 - $75.2 $ 105.5452%4630700
John Rogers 2013-12-31 Add 396.9%0.24%$58.9 - $75.2 $ 105.5452%324302
Ray Dalio 2013-12-31 New Buy0.02%$58.9 - $75.2 $ 105.5452%38621
George Soros 2013-12-31 Sold Out 0.02%$58.9 - $75.2 $ 105.5452%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Gilead Sciences Inc

Weekly CFO Sells Highlight: Affiliated Managers Group Inc., Gilead Sciences Inc., L-3 Communications Holdings Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Affiliated Managers Group Inc., Gilead Sciences Inc. and L-3 Communications Holdings Inc. Read more...
Weekly Insider Sells Highlight: ATHN, GILD, JPM, WAG
According to GuruFocus Insider Data, the largest insider sells during the past week were: AthenaHealth Inc, Gilead Sciences Inc, JPMorgan Chase & Co, and Walgreen Company. Read more...
Weekly CFO Sells Highlight: Gilead Sciences Inc., Micron Technology Inc., Adobe Systems Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Gilead Sciences Inc., Micron Technology Inc. and Adobe Systems Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 18.60
GILD's P/E(ttm) is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 18.60 )
GILD' s 10-Year P/E(ttm) Range
Min: 9.69   Max: 45.41
Current: 18.6

9.69
45.41
P/B 11.78
GILD's P/B is ranked higher than
63% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. GILD: 11.78 )
GILD' s 10-Year P/B Range
Min: 4.16   Max: 18.59
Current: 11.78

4.16
18.59
P/S 8.54
GILD's P/S is ranked higher than
84% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. GILD: 8.54 )
GILD' s 10-Year P/S Range
Min: 3.48   Max: 16.44
Current: 8.54

3.48
16.44
PFCF 17.39
GILD's PFCF is ranked higher than
98% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 17.39 )
GILD' s 10-Year PFCF Range
Min: 8.33   Max: 68.49
Current: 17.39

8.33
68.49
EV-to-EBIT 13.40
GILD's EV-to-EBIT is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 13.40 )
GILD' s 10-Year EV-to-EBIT Range
Min: -103.9   Max: 473.4
Current: 13.4

-103.9
473.4
PEG 2.27
GILD's PEG is ranked higher than
98% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 2.27 )
GILD' s 10-Year PEG Range
Min: 0.37   Max: 4.23
Current: 2.27

0.37
4.23
Shiller P/E 44.58
GILD's Shiller P/E is ranked higher than
96% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 44.58 )
GILD' s 10-Year Shiller P/E Range
Min: 17.87   Max: 1840.8
Current: 44.58

17.87
1840.8
Current Ratio 2.07
GILD's Current Ratio is ranked higher than
60% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. GILD: 2.07 )
GILD' s 10-Year Current Ratio Range
Min: 1.15   Max: 20.42
Current: 2.07

1.15
20.42
Quick Ratio 1.76
GILD's Quick Ratio is ranked higher than
60% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. GILD: 1.76 )
GILD' s 10-Year Quick Ratio Range
Min: 0.82   Max: 20.42
Current: 1.76

0.82
20.42

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 146.59
GILD's Price/Tangible Book is ranked higher than
61% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. GILD: 146.59 )
GILD' s 10-Year Price/Tangible Book Range
Min: 1.86   Max: 214.73
Current: 146.59

1.86
214.73
Price/DCF (Projected) 2.39
GILD's Price/DCF (Projected) is ranked higher than
96% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 2.39 )
GILD' s 10-Year Price/DCF (Projected) Range
Min: 0.77   Max: 20.81
Current: 2.39

0.77
20.81
Price/Median PS Value 0.91
GILD's Price/Median PS Value is ranked higher than
88% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. GILD: 0.91 )
GILD' s 10-Year Price/Median PS Value Range
Min: 0.41   Max: 4.65
Current: 0.91

0.41
4.65
Price/Peter Lynch Fair Value 1.00
GILD's Price/Peter Lynch Fair Value is ranked higher than
100% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 1.00 )
GILD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.4   Max: 9.13
Current: 1

0.4
9.13
Price/Graham Number 10.54
GILD's Price/Graham Number is ranked higher than
89% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 10.54 )
GILD' s 10-Year Price/Graham Number Range
Min: 1.59   Max: 15.08
Current: 10.54

1.59
15.08
Earnings Yield (Greenblatt) 7.50
GILD's Earnings Yield (Greenblatt) is ranked higher than
97% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. GILD: 7.50 )
GILD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 15
Current: 7.5

0.2
15
Forward Rate of Return (Yacktman) 21.19
GILD's Forward Rate of Return (Yacktman) is ranked higher than
83% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 15.36 vs. GILD: 21.19 )
GILD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.1   Max: 46.1
Current: 21.19

-0.1
46.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, BIIB, CELG, CMXHY » details
Traded in other countries:GIS.Germany, GILD.Mexico, GILD.Switzerland,
Gilead Sciences Inc was incorporated in Delaware on June 22, 1987. The Company is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. With each new discovery and experimental drug candidate, it seeks to improve the care of patients suffering from life-threatening diseases around the world. The Company's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Australia. It markets products in the HIV/AIDS, liver diseases, respiratory and cardiovascular/metabolic therapeutic areas. The Company's products comprise Truvada is an oral formulation dosed once a day as part of combination therapy to treat human immunodeficiency virus infection in adults. Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Viread is an oral formulation of a nucleotide analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Emtriva is an oral formulation of a nucleoside analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Hepsera is an oral formulation of a nucleotide analogue polymerase inhibitor, dosed once a day to treat chronic hepatitis B. AmBisome is a proprietary liposomal formulation of amphotericin B, an antifungal agent to treat serious invasive fungal infections caused by various fungal species. Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. Ranexa is indicated for the treatment of chronic angina. Vistide is an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS. Cayston is an inhaled antibiotic as a treatment to improve respiratory systems in cystic fibrosis patients with Pseudomonas aeruginosa. The Company has U.S. and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. The Company sells and distributes Truvada, Viread, Emtriva, Hepsera and AmBisome in Asia, Australia, Europe, Latin America, the Middle East and New Zealand either through its commercial teams, third party distributors or corporate partners. The Company's products and development programs target a number of areas, including viral, fungal, respiratory and cardiovascular diseases. The Company's products compete with other available products based mainly on: efficacy; safety; tolerability; acceptance by doctors
» More Articles for GILD

Headlines

Articles On GuruFocus.com
Is it Time to Sell Gilead Sciences? Dec 18 2014 
Druckenmiller Adds Healthcare Stocks to Portfolio Dec 15 2014 
Weekly CFO Sells Highlight: Coco-Cola Co, Gilead Sciences Inc, AutoZone Inc. Dec 14 2014 
Weekly Insider Sells Highlight: WAT, KO, GILD, AZO, MAS Dec 14 2014 
T Rowe Price's Top Stakes for the Third Quarter Dec 09 2014 
3 Strong Buys and Sells Dec 08 2014 
Gilead Sciences' Recent Plunge Makes It One of The Hot Stocks To Buy Dec 01 2014 
now Nov 29 2014 
Weekly CFO Sells Highlight: Tableau Software Inc, Gilead Sciences Inc, Facebook Inc. Nov 16 2014 
Gilead Sciences Releases Impressive Results for Hepatitis C Drug Nov 12 2014 


More From Other Websites
ONO and Gilead Announce Exclusive License Agreement to Develop BTK Inhibitor, ONO-4059, for the... Dec 19 2014
ONO AND GILEAD ANNOUNCE EXCLUSIVE LICENSE AGREEMENT TO DEVELOP BTK INHIBITOR, ONO-4059, FOR THE... Dec 19 2014
ONO and Gilead Announce Exclusive License Agreement to Develop BTK Inhibitor, ONO-4059, for the... Dec 19 2014
ONO and Gilead Announce Exclusive License Agreement to Develop BTK Inhibitor, ONO-4059, for the... Dec 19 2014
Lawsuit Alleges Price Gouging by Maker of Hepatitis Drug Dec 19 2014
Drug’s Price Sparks Lawsuit Dec 18 2014
CVS' Plan to Foment a Hep C Pricing War Between Gilead, Abbvie Dec 18 2014
Biotech: More Upside in 2015? Dec 18 2014
2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses Dec 18 2014
Meet 5 Big Tech Stocks Expected To See Profits Surge Dec 16 2014
Viekirax/Exviera vs. Harvoni: Clash of the Hep C Drugs 2015 Dec 16 2014
Where is Santa rally? Dec 15 2014
Gilead Sciences: What Its New Hire Means for Its Cancer Pipeline Dec 15 2014
DMG MORI opens Global Headquarters in Winterthur New innovative technology centre in Switzerland Dec 15 2014
Philippe C. Bishop, MD, to Join Gilead as Senior Vice President, Hematology and Oncology... Dec 15 2014
Philippe C. Bishop, MD, to Join Gilead as Senior Vice President, Hematology and Oncology... Dec 15 2014
Meet 5 Top Biotech Stocks Holding Up In Shaky Market Dec 13 2014
These 2 Biotech Stocks Are Set To Split The $15 Billion Hepatitis C Market Dec 12 2014
Gilead Sciences: Hep-C Scripts Go Down to the Wire Dec 12 2014
Philadelphia transit system sues Gilead Sciences over $1,000-a-pill drug Dec 11 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK